ClinicalTrials.gg
Not yet recruitingNCT05990712Updated Aug 14, 2023

The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammatory Markers

A Phase 4 interventional study of Omega-3 and Trehalose in Dry Eye, Dry Eye Syndromes and Cataract, sponsored by Uptown Eye Specialists. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Uptown Eye Specialists · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing omega-3 fatty acid in Dry Eye Syndromes — 1 open to participants now, 1 under way, none of them phase 3. omega-3 fatty acid · Dry Eye Syndromes.

Planned enrollment
6th of 11
68 · median 68
Started
2023
with 1 other
Phase 4
Only one
of the 11
Registered
11th of 11
by date
Lead sponsor
1 of 11
Uptown Eye Specialists

Among the 11 studies testing omega-3 fatty acid in Dry Eye Syndromes, this one is the 6th largest by planned enrollment, is one of 2 that started in 2023, is the only one in phase 4, and was the 11th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 11 studies testing omega-3 fatty acid in Dry Eye Syndromes is open now, in 1 country.

By country, each count listing its studies:

About omega-3 fatty acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing omega-3 fatty acid in Dry Eye Syndromes, or all of them as a file.
02

Study summary

This study assesses the impact of two differing ocular hygiene regimens prior to cataract surgery. The first regimen includes an omega-3 supplement and the second without, and both include an at-home lid wipe and cleansing eye drops. These regimens will be assessed on microbial load, inflammation, tear osmolarity, and dry eye metrics. Patients will be randomized to either the omega-3 group + 3-part hygiene regimen, or the group with only the 3-part hygiene regimen. Data will be collected for inflammation through a test (InflammaDry) that measures an inflammatory marker, dry eye metrics via an imaging tool called Oculus 5M and the Canadian Dry Eye Assessment (CDEA) questionnaire, tear osmolarity through Tear Labs device, and area of growth for conjunctiva microbial load by swabbing the conjunctiva of the eye. Dry eye metrics (CDEA and Oculus 5M) will be collected during the patient's baseline appointment, 2-5 days prior to surgery, and post-operative month 1. Microbial load swabs will be collected at baseline, 2-5 days prior to surgery, and date of the surgery. An ocular assessment will also be completed at baseline, one week post-operation, and one month post-operation. All metrics will be compared to the fellow eye. The usage of omega-3 will be compared to the regimen without omega-3.

Read the detailed description

Prospective interventional study assessing the impact of two ocular hygiene regimens, with and without Omega-3, on microbial load, inflammation, tear osmolarity, and dry eye metrics and disease for patients soon to undergo cataract surgery. Study recruitment will occur at Uptown Eye between Sept-Nov 2023, with a target of 68 patients enrolled in the study. Patients will be consecutively randomized to group 1 (without omega 3 group) or group 2 (with omega 3 group). The intervention includes Zocular in clinic at baseline, Thealoz Duo eyedrops twice daily until surgery, and the cleansing wipes twice daily until surgery. The omega 3 group will take the supplement from baseline until one month post-operative.

Data will be collected for inflammation through a InflammaDry Matrix metallopeptidase 9 (MMP-9) test, dry eye through Oculus 5M (measures non-invasive break-up time (NIBUT), lipid layer, bulbar redness, tear meniscus height) and Canadian Dry Eye Assessment (CDEA), TearLab for osmolarity, and conjunctival swabs for microbial load. Dry eye metrics (CDEA and Oculus 5M) will be collected during the patient's baseline Cataract Dry Eye Clinic (CDEC) appointment, 2-5 days prior to surgery, and post-operative month 1. Microbial load will be collected at baseline, 2-5 days prior to surgery, and date of the surgery. Tear osmolarity and inflammation markers will be collected at baseline, 2-5 days prior to surgery, and post-operative month. An ocular assessment will also be completed at baseline, one week post-operation, and post-operative month. All metrics will be compared to the fellow eye.

03

Conditions studied

  • Dry Eye
  • Dry Eye Syndromes
  • Cataract

Keywords

  • Pre-operative
  • Ocular hygiene
  • Omega 3
  • Microbial load
  • Inflammation
  • Tear osmolarity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 or older who underwent cataract surgical ocular hygiene treatment regimen prior to cataract surgery.
  • Patients of all severity of dry eye will be included.

Exclusion criteria

Exclusion Criteria:

  • Patients with any other ocular comorbidities (glaucoma, iritis, traumatic eye injury, known systemic diseases, immune disorders, anti-inflammatory medications, blood disorders (eg. altered white counts), prior surgery, prior traumatic eye injury, previous dry eye interventions such as ocular plugs, radiofrequency, and IPL).
  • Patients who have any complications arise during the cataract surgery.
  • Patients with altered mental state and cannot provide .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Omega-3

    Participants in this arm will take oral omega-3 supplement for 4 weeks pre-operatively and 4 weeks post-operatively. They will also receive the Zocular intervention in clinic and the lid wipe and Thealoz eyedrops at home.

    Dietary Supplement: Omega-3 · Drug: Trehalose · Drug: Zocular Eyelid System Treatment · Other: Blephadex cleansing eyelid wipes

  • Active comparator
    No Omega-3

    Participants in this arm will not take oral omega-3 supplement. They will only receive the Zocular intervention in clinic and the lid wipe and Thealoz eyedrops at home.

    Drug: Trehalose · Drug: Zocular Eyelid System Treatment · Other: Blephadex cleansing eyelid wipes

Interventions

  • Dietary supplementOmega-3 fatty acidStudies of Omega-3 fatty acidOmega-3 fatty acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Omega-3 is a fatty acid and there is evidence that the consumption of re-esterified oral omega-3 supplements over the course of 6 to 8 weeks aid in reducing inflammation, dry eye, and optimizing tear osmolarity. The oral omega-3 supplement taken daily.

  • Eyedrops consisting of trehalose and sodium hyaluronate that lubricate and hydrate the eye to relieve dry eye.

    Also known as: Thealoz Duo Drops

  • DrugZocular Eyelid System Treatment

    A lid cleaning and debridement system that consists of okra-based gel to relieve dry eye or inflammation. The gel is applied to the eyelid margin and lashes with a cotton swab.

    Also known as: ZEST

  • OtherBlephadex cleansing eyelid wipes

    Eyelid cleansing wipes with tea tree oil and coconut that help reduce infection.

06

What researchers measure

Primary outcomes

  1. MMP-9

    Level of MMP-9, an inflammatory marker reported as positive (level of MMP-9 \> 40ng/mL) or negative (level of MMP-9 \< 40ng/mL).

    Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1

  2. Microbial load

    Area of microbial growth from conjunctival swab reported as percentage of dish coverage, incubated for 48 hours

    Time frame: Baseline, 2-5 days prior to surgery, surgery day

  3. Tear osmolarity

    Measure of salt concentration in tear reported as mOsm/L

    Time frame: Baseline, 2-5 days prior to surgery, surgery day

Secondary outcomes

  1. Non-invasive break-up time (NIBUT)

    Non-invasive break-up time (NIBUT) is measured using the Oculus 5M and measured in seconds, with longer NIBUT representing better outcomes.

    Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1

  2. Lipid layer

    Lipid layer is reported in nanometres with higher/thicker lipid layers representing a better outcome.

    Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1

  3. Bulbar redness

    Bulbar redness is reported by a score from 0-4 with lower scores representing a better outcome.

    Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1

  4. Tear meniscus height

    Tear meniscus height (TMH) is reported in millimetres, with increases in TMH representing a better outcome.

    Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1

  5. Canadian Dry Eye Assessment (CDEA) Questionnaire

    12 item questionnaire for reporting of dry eye symptoms on a scale of 0-4. Total scores for the CDEA questionnaire range from 0 to 48 and are interpreted as no dry eye symptoms or normal (\<5), mild dry eye symptoms (5-20), moderate dry eye symptoms (21-30), or severe dry eye symptoms (31-48).

    Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Jan 2024, 4 months later.

Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 4 months is below that.

Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2023
First posted
Aug 14, 2023
StartEst.
Sep 1, 2023
Primary completionEst.
Jan 1, 2024
CompletionEst.
Jan 1, 2024
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05990712
Lead sponsor
Uptown Eye Specialists
Collaborators
WIlliam Osler Health Systems, Forsee Canada
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Sep 1, 2023 (estimated)
Primary completion
Jan 1, 2024 (estimated)
Completion
Jan 1, 2024 (estimated)
Last update
Aug 14, 2023

Study contacts

Sohel Somani, MD
Contact
sohel.somani@uptowneye.ca
416-292-0330

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omega-3 fatty acid

Start the discussion